-
公开(公告)号：US11999952B2
公开(公告)日：2024-06-04
申请号：US17236660
申请日：2021-04-21
Applicant: TOOLGEN INCORPORATED , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , SEOUL NATIONAL UNIVERSITY HOSPITAL
Inventor： Jeong Hun Kim , Sung Wook Park , Seokjoong Kim , Dong Woo Song
IPC: C12N15/00 , A61K9/00 , A61K38/46 , A61K48/00 , C07K14/47 , C07K14/515 , C07K14/52 , C12N9/22 , C12N15/11 , C12N15/113 , C12N15/86
CPC classification number: C12N15/11 , A61K9/0048 , A61K38/465 , A61K48/00 , A61K48/005 , C07K14/4702 , C07K14/515 , C07K14/52 , C12N9/22 , C12N15/113 , C12N15/1136 , C12N15/86 , A01K2227/105 , A01K2267/03 , C12N2310/20 , C12N2750/14143 , Y02A50/30
Abstract: The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularization-associated factor for regulating neovascularization and/or a composition for artificially manipulating the neovascularization-associated factor. In a specific aspect, a neovascularization regulatory system including a neovascularization-associated factor such as artificially manipulated VEGFA, HIF1A, ANGPT2, EPAS1, or ANGPTL4 and/or an expression product thereof is provided.
-
公开(公告)号：US20240082305A1
公开(公告)日：2024-03-14
申请号：US18262303
申请日：2022-01-20
Applicant: Seoul National University R&DB Foundation , Seoul National University Hospital , The Asan Foundation
Inventor： Jaeseok YANG , Sun-Kyung LEE , Joon Young JANG , Junho CHUNG , Jerome HAN , Nara SHIN , Hyori KIM
IPC: A61K35/17 , A61K39/00 , A61P37/06 , C07K16/28 , C12N5/0783
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/46433 , A61P37/06 , C07K16/2833 , C12N5/0637 , A61K2239/13 , A61K2239/17 , A61K2239/21
Abstract: Antibody-mediated rejection (ABMR) is one of the main obstacles to successful transplantation, including ABO blood group-incompatible (ABOi) transplantation. C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues. Described herein are anti-C4d CAR Tregs that suppress ABMR in ABOi allografts. Anti-C4d CAR Tregs prepared by retroviral transduction of CAR into CD62L +CD4 +CD25 +Tregs, expressed Foxp3, CD25, CTLA-4, LAP, and GITR to similar extents as non-transduced Tregs. Anti-C4d CAR Tregs were activated by specific binding to C4d and suppressed in vitro T cell proliferation as well as non-transduced Tregs. Furthermore, adoptive transfer of anti-C4d CAR Tregs significantly prolonged mouse ABOi heart allograft survival (P
-
公开(公告)号：US20230310249A1
公开(公告)日：2023-10-05
申请号：US17915934
申请日：2021-03-31
Inventor： Nam-Jong Paik , Jihong Park , Yong-Lae Park , Junghan Kwon
CPC classification number: A61H1/024 , A61H2003/007 , A61F5/0111 , A61F5/0109
Abstract: Disclosed is a robotic orthosis for a lower extremity for gait rehabilitation training, comprising a knee stretching member which is provided to be installable on the knee so as to enable the knee joint to be stretched in a swing phase and enable a state in which the knee is stretched to be maintained in a stance phase. The knee stretching member comprises: a knee sleeve surrounding the knee joint; and a knee supporting chamber which is mounted so as to be connected to the knee sleeve, and which, when air is introduced therein and is inflated in the swing phase, enables the knee to be stretched by supporting the knee joint, and enables the state in which the knee is stretched to be maintained in the stance phase.
-
公开(公告)号：US11530377B2
公开(公告)日：2022-12-20
申请号：US17054999
申请日：2019-12-10
Inventor： Seung Hee Yang , Yon Su Kim , Dong Ki Kim , Sa Ram Lee , Yong Chul Kim , Mi Yeon Yu , Ji Eun Kim
Abstract: The bioenvironmental simulation device according to an embodiment of the present invention includes at least one mounting unit on which cells to be measured are placed, a rotational force application unit configured to rotate the mounting unit so as to apply a rotational force to the cells to be measured placed on the mounting unit, and a culture liquid flow device through which a culture liquid flows across the mounting unit, wherein the culture liquid flows by the culture liquid flow device so as to apply a shear force to the cells to be measured.
-
公开(公告)号：US20220339263A1
公开(公告)日：2022-10-27
申请号：US17677162
申请日：2022-02-22
Inventor： Keon Wook KANG , Myung Geun SONG , Cho Rong PARK , Yun-Sang LEE , Hye Won YOUN , Ji Yong PARK , Se Ra OH
Abstract: A composition for treatment of a cancer according to an embodiment of the present disclosure expresses secreted protein acidic and rich in cysteine (SPARC). The composition includes an albumin and at least one cysteine bound thereto.
-
Patent Agency Ranking
公开(公告)号：US20220339026A1
公开(公告)日：2022-10-27
申请号：US17626972
申请日：2020-07-15
Inventor： Hyung-Ho Kim , Koo Tae Kang
Abstract: Disclosed are: a system comprising a gas circulation device capable of circulating hyperthermic gas in the peritoneal cavity and a temperature control device; and a system comprising a drug spray device for effectively spraying a drug in the peritoneal cavity together with gas. The systems of the present invention are used as systems for hyperthermic intraperitoneal chemotherapy and can maximize the anticancer therapy effect by more effectively delivering a small amount of an anticancer drug to cancer cells while maintaining the temperature of gas in the peritoneal cavity at a predetermined temperature.
-
公开(公告)号：US20220319593A1
公开(公告)日：2022-10-06
申请号：US17371872
申请日：2021-07-09
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , Foundation for Research and Business, Seoul National University of Science and Technology
Inventor： Hyun KIM , Hyo Keun LEE , Seung Yong LEE , Hyuk Jae LEE
IPC: G11C13/00
Abstract: Provided is a phase-change memory (PCM) module including a PCM device including a bit line and a word line, a memory controller configured to output a command related to an operation of the PCM device, and an interference mitigation part located between the memory controller and the PCM device and configured to perform a rewrite operation on the basis of a state transition characteristic of the command output from the memory controller.
-
公开(公告)号：US11462266B1
公开(公告)日：2022-10-04
申请号：US17371872
申请日：2021-07-09
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , Foundation for Research and Business, Seoul National University of Science and Technology
Inventor： Hyun Kim , Hyo Keun Lee , Seung Yong Lee , Hyuk Jae Lee
Abstract: Provided is a phase-change memory (PCM) module including a PCM device including a bit line and a word line, a memory controller configured to output a command related to an operation of the PCM device, and an interference mitigation part located between the memory controller and the PCM device and configured to perform a rewrite operation on the basis of a state transition characteristic of the command output from the memory controller.
-
公开(公告)号：US20210214667A1
公开(公告)日：2021-07-15
申请号：US17054999
申请日：2019-12-10
Inventor： Seung Hee YANG , Yon Su KIM , Dong Ki KIM , Sa Ram LEE , Yong Chul KIM , Mi Yeon YU , Ji Eun KIM
Abstract: The bioenvironmental simulation device according to an embodiment of the present invention includes at least one mounting unit on which cells to be measured are placed, a rotational force application unit configured to rotate the mounting unit so as to apply a rotational force to the cells to be measured placed on the mounting unit, and a culture liquid flow device through which a culture liquid flows across the mounting unit, wherein the culture liquid flows by the culture liquid flow device so as to apply a shear force to the cells to be measured.
-
公开(公告)号：US20180016552A1
公开(公告)日：2018-01-18
申请号：US15506736
申请日：2015-08-27
Inventor： Sung Sup PARK , Ji Yeon KIM
CPC classification number: C12N5/0621 , A61K35/30 , C12N2501/105 , C12N2501/115 , C12N2501/155 , C12N2501/385 , C12N2501/41 , C12N2501/415 , C12N2501/599 , C12N2506/02 , C12N2506/45 , G01N33/5058 , G01N2800/168
Abstract: Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.
-
-
-
-
-
-
-
-
-
Search Results
2907
records
(took 0.032 seconds)
